Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 5Triple Negative Breast Neoplasms 4Neoplasms 2Esophageal Squamous Cell Carcinoma 2Biliary Tract Neoplasms 2Advanced Gastric Cancer 2Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Rectal Neoplasms 1Pyloric Stenosis, Hypertrophic 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Pleural Effusion, Malignant 1Pancreatic Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Lung Diseases 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced or Metastatic Gastric Adenocarcinoma 1Hepatic Metastasis of Colorectal Cancer 1Esophageal Neoplasms 1Disease Progression 1Colorectal Neoplasms 1Colorectal Cancer Recurrent 1Carcinoma, Non-Small-Cell Lung 1CRC 1

Interventions

camrelizumab 1apatinib 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Locally Advanced or Metastatic Gastric Adenocarcinoma × camrelizumab × Clear all
NCT04572542 2020-10-01

Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer

The First Affiliated Hospital of Xiamen University

Phase 1/2 Unknown
46 enrolled
Gastrointestinal

Locally Advanced or Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡